What is DXCM stock price target for 2026?

WallStSmart's 12-month price target for DexCom Inc is $63.19, representing 9.8% upside from the current price of $57.56.

What is DXCM stock forecast?

DexCom Inc forecast includes bull, base, and bear case scenarios from 2026 through 2030. Revenue and EPS projections are derived from analyst consensus and conservative extrapolation with growth deceleration for outer years.

Is DXCM undervalued based on price targets?

Our DCF intrinsic value for DexCom Inc is $665.12, against a current price of $57.56. The margin of safety is 89.75%.

DXCM

DexCom Inc

NASDAQ: DXCM · HEALTHCARE · MEDICAL DEVICES

$57.56

-2.97% today

Updated 2026-04-29

Market cap

$22.21B

P/E ratio

27.54

P/S ratio

4.76x

EPS (TTM)

$2.09

Dividend yield

—

52W range

$54 – $90

Volume

4.1M

Market cap

$22.21B

P/E ratio

27.54

P/S ratio

4.76x

EPS (TTM)

$2.09

Dividend yield

—

52W range

$54 – $90

Volume

4.1M

DexCom Inc (DXCM) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current

$57.56

Consensus

$85.33

+48.25%

2030 Target

$261.32

+354.00%

DCF

$665.12

+89.75% MoS

Current price

$57.56

Analyst consensus

$85.33

+48.25%

2030 Target

$261.32

+354.00%

Intrinsic (DCF)

$665.12

+89.75% MoS

21 analysts:

8 Buy2 Hold2 Sell

Management guidance

DexCom provided 2026 revenue guidance of $5.34B (14.48% growth) and 2027 guidance of $6.00B (12.39% growth) in their most recent earnings report. Management has emphasized margin expansion opportunities and reacceleration of the US CGM market, with strong G7 adoption and international expansion driving growth through 2028.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range

Bull case (2030)

$435.54

$8.5B Rev × 20x P/S

Base case (2030)

$261.32

$8.5B Rev × 12x P/S

Bear case (2030)

$174.22

$8.5B Rev × 8x P/S

Financial forecast — research-backed

Metric	2023	2024	2025	2026 (E)	2027 (E)	2029 (E)	2030 (E)
Revenue	$3.6B	$4.0B	$4.7B	$5.3B	$6.0B	$7.6B	$8.5B
Revenue growth	—	11.3%	15.6%	14.5%	12.4%	12.4%	12.2%
EPS	$1.51	$1.58	$2.09	$2.54	$3.04	$4.29	$4.95
P/S ratio	—	—	—	12.0x	12.0x	12.0x	12.0x
Implied price	—	—	—	$161.77	$186.66	$236.44	$261.32

Catalysts & risks

Growth catalysts

+ G7 system market share gains and international expansion (Europe, Asia markets)

+ Stelo product line expansion for Type 2 diabetes and non-diabetic populations

+ Gross and operating margin expansion from 2026-2028 (TD Cowen raised estimates)

+ US CGM market reacceleration after recent slowdown concerns

+ Potential partnerships/integrations with digital health platforms and insulin delivery systems

Key risks

- US continuous glucose monitoring market slowdown concerns noted by multiple analysts

- Competitive pressure from Abbott FreeStyle Libre and Medtronic MiniMed (post-spinoff)

- Regulatory risks related to OTC expansion and new product categories

- International reimbursement and pricing pressure in key markets

- Recent stock underperformance (-32% in 5 years) despite strong fundamentals suggests valuation compression risk

Methodology

DexCom Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 21 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.